Concepedia

Yan Song

YS

51

Publications

1.8K

Citations

24

H-Index

2005

Active since

Affiliations

Analysis Group (United States)(Current)

Chinese Academy of Medical Sciences & Peking Union Medical College

AbbVie (United States)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Astellas Pharma (United States)

Yan Song is an author at Analysis Group (United States) specializing in medicine, oncology, and pathology.

Top concepts

MedicineOncologyPathologyCancer ResearchRadiation OncologyHealthUrologyCancer TherapyPharmacologyHealth Policy

Publications per year

2005–2024

51

Publications

51

Loss of FOXA1/2 Is Essential for the Epithelial-to-Mesenchymal Transition in Pancreatic Cancer

Yan Song, M. Kay Washington, Howard C. Crawford · Cancer Research · 2010 · 253 citations · Full text

Pathology, Cancer Biology, Tumor Biology +16

Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

Aiping Zhou, Yuxian Bai, Yan Song et al. · The Oncologist · 2019 · 115 citations · Full text

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial

Jing Huang, Juxiang Xiao, Wentao Fang et al. · Cancer Medicine · 2021 · 112 citations · Full text

PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance

Nilotpal Roy, Kenneth K. Takeuchi, Jeanine Ruggeri et al. · Genes & Development · 2016 · 99 citations · Full text

Aberrant Activation, Embryonic Signaling Pathways, Pancreatic Cancer +10

Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).

Sant P. Chawla, Jean‐Yves Blay, I. L. Ray-Coquard et al. · Journal of Clinical Oncology · 2011 · 77 citations

Mtor Inhibitor Ridaforolimus, Advanced Sarcoma Patients, Pfs Events +15

Rows per page

1–5 of 51